Krystal Biotech, Inc.
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
KRYS$306.50+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of and
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (in thousands, except par value) | 2025 | 2024 |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $496,304 | $344,865 |
| Short-term investments | 331,487 | 252,652 |
| Accounts receivable, net | 127,425 | 104,746 |
| Inventory | 40,475 | 26,508 |
| Prepaid taxes | 14,006 | 1,617 |
| Prepaid expenses and other current assets | 14,905 | 11,657 |
| Total current assets | 1,024,602 | 742,045 |
| Property and equipment, net | 150,776 | 155,168 |
| Long-term investments | 128,066 | 152,114 |
| Right-of-use assets | 7,239 | 6,280 |
| Deferred tax asset, net of valuation allowance | 22,824 | — |
| Other non-current assets | 287 | 231 |
| Total assets | $1,333,794 | $1,055,838 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $3,238 | $4,985 |
| Current portion of lease liability | 1,771 | 1,217 |
| Accrued rebates | 58,181 | 36,804 |
| Accrued expenses and other current liabilities | 39,752 | 58,989 |
| Total current liabilities | 102,942 | 101,995 |
| Lease liability | 7,568 | 6,044 |
| Other long-term liabilities | 3,724 | 1,419 |
| Total liabilities | 114,234 | 109,458 |
| Commitments and contingencies (see note 7) | ||
| Stockholders' equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of December 31, 2025 and 2024; 29,192 and 28,794 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | — | — |
| Additional paid-in capital | 1,194,261 | 1,127,238 |
| Accumulated other comprehensive income (loss) | 1,136 | (190) |
| Retained earnings (accumulated deficit) | 24,163 | (180,668) |
| Total stockholders’ equity | 1,219,560 | 946,380 |
| Total liabilities and stockholders’ equity | $1,333,794 | $1,055,838 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.